Abstract
Testing positivity rate is currently used both as a benchmark of testing adequacy and for assessing the evolution of COVID-19 pandemic 1,2. However, since the former is a prerequisite for the latter, its interpretation is often conflicting. We propose as a benchmark for COVID-19 testing effectiveness a new metric, termed “Severity Detection Rate” (SDR), that represents the daily needs for new Intensive Care Unit (ICU) admissions, per 100 cases detected (t-i) days ago, per 10,000 tests performed (t-i) days ago. Based on the announced COVID-19 monitoring data in Greece from May 2020 until January 2021, we show that beyond a certain threshold of daily tests, SDR reaches a plateau of very low variability that begins to reflect testing adequacy. Due to the stabilization of SDR, it was possible to predict with great accuracy the daily needs for new ICU admissions, 12 days ahead of each testing data point, over a period of 6 months, with Pearson r = 0.99 (p = 10−180), RMSE = 4,34. We strongly believe that this metric will help in guiding the timely decisions of both scientists and government officials to tackle pandemic spread and prevent ICU overload by setting effective testing requirements for accurate pandemic monitoring. We propose the further study of this novel metric with data from more countries to confirm the validity of the current findings.
Competing Interest Statement
All authors are employed by Bioiatriki Healthcare Group
Funding Statement
No specific funding was received for this study. All authors are employed by Bioiatriki Healthcare Group.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB/oversight body approvals were required for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Changed the title to better reflect content. Reworked the narrative of Results and Discussion sections for better clarity. Various minor amendments throughout the manuscript. No changes made in the data and scientific conclusions.
Data Availability
All primary data used are publicly available.
https://eody.gov.gr/epidimiologika-statistika-dedomena/ektheseis-covid-19/